-
1Academic Journal
Συγγραφείς: O.Yе. Fartushna, H.V. Palahuta, S.K. Yevtushenko
Πηγή: INTERNATIONAL NEUROLOGICAL JOURNAL; Vol. 17 No. 1 (2021); 17-22
МЕЖДУНАРОДНЫЙ НЕВРОЛОГИЧЕСКИЙ ЖУРНАЛ; Том 17 № 1 (2021); 17-22
МІЖНАРОДНИЙ НЕВРОЛОГІЧНИЙ ЖУРНАЛ; Том 17 № 1 (2021); 17-22Θεματικοί όροι: 03 medical and health sciences, 0302 clinical medicine, COVID-19, SARS-CoV-2, гострий мієліт, неврологічні прояви, нейропсихічні прояви, ускладнення, клінічний випадок, огляд, COVID-19, SARS-CoV-2, острый миелит, неврологические проявления, нейропсихические проявления, осложнения, клинический случай, обзор, COVID-19, SARS-CoV-2, acute myelitis, neurological presentations, neuropsychiatric presentations, complications, case report, review, 3. Good health
Περιγραφή αρχείου: application/pdf
-
2Academic Journal
Συγγραφείς: G. M. Koilubaeva, E. A. Aseeva, S. K. Solovyev, N. Yu. Nikishina, E. L. Nasonov, А. S. Dzhumagulova, N. P. Tkachenko, Е. R. Karimova, A. A. Moldobaeva, A. Zh. Zhumakadyrova, Г. М. Койлубаева, Е. А. Асеева, С. К. Соловьев, Н. Ю. Никишина, Е. Л. Насонов, А. С. Джумагулова, Н. П. Ткаченко, Э. Р. Каримова, А. А. Молдобаева, А. Ж. Жумакадырова
Συνεισφορές: Настоящее исследование выполнено в рамках фунамен-тальной научной темы N AAA-A19-119021190145-2 по фрагменту «РЕНЕССАНС»
Πηγή: Rheumatology Science and Practice; Vol 58, No 1 (2020); 106-111 ; Научно-практическая ревматология; Vol 58, No 1 (2020); 106-111 ; 1995-4492 ; 1995-4484
Θεματικοί όροι: анти-В-клеточная терапия, ритуксимаб, neuropsychiatric manifestations, central nervous system, peripheral nervous system, anti-B-cell therapy, rituximab, нейропсихические проявления, центральная нервная система, периферическая нервная система
Περιγραφή αρχείου: application/pdf
Relation: https://rsp.mediar-press.net/rsp/article/view/2851/1937; Насонов ЕЛ. Клинические рекомендации по ревматологии. 2-е изд., испр. и доп. Москва: ГЭОТАР-Медиа; 2010. C. 42981; The American College of Rheumatology nomenclature and case definitions for neuropsychiatric lupus syndromes. Arthritis Rheum. 1999;42(4):599-608. doi:10.1002/1529-0131(199904)42:43.0.CO;2-F; Piga M, Mathieu A. Managing CNS involvement in systemic lupus erythematosus. Int JClin Rheumatol. 2011;6:547-67. doi:10.2217/ijr.11.44; Bortoluzzi A, Scire CA, Bombardieri S, et al. Development and validation of a new algorithm for attribution of neuropsychiatric events in systemic lupus erythematosus. Rheumatology (Oxford). 2015;54(5):891-8. doi:10.1093/rheumatology/keu384; Piga M, Casula L, Perra D, et al. Population-based analysis of hospital-izations in a West-European region revealed major changes in hospital utilization for patients with systemic lupus erythematosus over the period 2001-2012. Lupus. 2016;25:28-37. doi:10.1177/0961203315596597; Hanly JG, Urowitz MB, Su L, et al. Short-term outcome of neu-ropsychiat-ric events in systemic lupus erythematosus upon enrollment into an inter-national inception cohort study. Arthritis Rheum. 2008;59(5):721-9. doi:10.1002/art.23566; Zirkzee EJ, Huizinga TW, Bollen EL, et al. Mortality in neuropsychiatric systemic lupus erythematosus (NPSLE). Lupus. 2014;23:31-8. doi:10.1177/0961203313512540; Piga M, Chessa E, Peltz MT, et al. Demyelinating syndrome in SLE encompasses different subtypes: do we need new classification criteria? Pooled results from systematic literature review and monocentric cohort analysis. Autoimmun Rev. 2017;16(3):244-52. doi:10.1016/j.autrev.2017.01.011; Hanly JG, Urowitz MB, Sanchez-Guerrero J, et al. Neuropsychiatric events at the time of diagnosis of systemic lupus erythematosus: an international inception cohort study. Arthritis Rheum. 2007;56(1):265-73. doi:10.1002/art.22305; Bertsias GK, Ioannidis JP, Aringer M, et al. EULAR recommen-da-tions for the management of systemic lupus erythematosus with neuropsychiatric manifestations: report of a task force of the EULAR standing committee for clinical affairs. Ann Rheum Dis. 2010;69(12):2074-82. doi:10.1136/ard.2010.130476; Ezeonyeji AN, Isenberg DA. Early treatment with rituximab in newly diagnosed systemic lupus erythematosus patients: a steroidsparing regimen. Rheumatology (Oxford). 2012;51(3):476-81. doi:10.1093/rheumatology/ker337; Pepper R, Griffith M, Kirwan C, et al. Rituximab is an effective treat-ment for lupus nephritis and allows a reduction in maintenance steroids. Nephrol Dial Transplant. 2009;24(12):3717-23. doi:10.1093/ndt/gfp336; Petri M, Orbai A, Alarson G, et al. Derivation and validation of the Systemic Lupus International Collaborating Clinics Classification Criteria for Systemic lupus erythematosus. Arthritis Rheum. 2012;64(8):2677-86. doi:10.1002/art.34473; Shessa E, Piga M, et al. Severe neuropsychiatric systemic lupus erythematosus successfully treated with rituximab an alternative to standard of care. Open Access Rheumatology: Research and Reviews, 11 September, 2017. P. 167-8. doi:10.2147/OARRR.S143768; Steri M, Orru V, Idda ML, et al. Overexpression of the cytokine BAFF and autoimmunity risk. N Engl J Med. 2017;376(17):1615-26. doi:10.1056/NEJMoa1610528; Wahren-Herlenius M, Dorner T. Immunopathogenic mechanisms of systemic autoimmune disease. Lancet. 2013;382(9894):819-31. doi:10.1016/S0140-6736(13)60954-X; Floris A, Piga M, Cauli A, Mathieu A. Predictors of flares in systemic lupus erythematosus: preventive therapeutic intervention based on serial anti-dsDNA antibodies assessment. Analysis of a monocentric cohort and literature review. Autoimmun Rev. 2016;15(7):656-63. doi:10.1016/j.autrev.2016.02.019; Lee DM, Friend DS, Gurish MF, et al. Mast cells: a cellular link between autoantibodies and inflammatory arthritis. Science. 2002;297(5587):1689-92. doi:10.1126/science.1073176; Lovgren T, Eloranta ML, Bave U, et al. Induction of interferon-alpha production in plasmacytoid dendritic cells by immune complexes containing nucleic acid released by necrotic or late apoptotic cells and lupus IgG. Arthritis Rheum. 2004;50(6):1861-72. doi:10.1002/art.20254; Martin F, Chan AC. B-cell immunobiology in disease: evolving concepts from the clinic. Ann Rev Immunol. 2006;24:467-96. doi:10.1146/annurev.immunol.24.021605.090517; Vallin H, Perers A, Alm GV, Ronnblom L. Anti-double-stranded DNA antibodies and immu-nostimulatory plasmid DNA in combination mimic the endogenous IFN-alpha inducer in systemic lupus erythematosus. J Immunol. 1999;163(11):6306-13.; Piga M, Gabba A, Cauli A, et al. Rituximab treatment for 'rhupus syndrome': clinical and power-Doppler ultraso-nographic monitoring of response. A longitudinal pilot study. Lupus. 2013;22 (6):624-8. doi:10.1177/0961203313482741; Narvaez J, Rios-Rodriguez V, de la Fuente D, et al. Rituximab therapy in refractory neuropsychiatric lupus: current clinical evidence. Semin Arthritis Rheum. 2011;41:364-72. doi:10.1016/j.semarthrit.2011.06.004; Tokunaga M, Saito K, Kawabata D, et al. Efficacy of rituximab (anti-CD20) for refractory systemic lupus erythematosus involving the central nervous system. Ann Rheum Dis. 2007;66 (4):470-5. doi:10.1136/ard.2006.057885; Hanly JG. Diagnosis and management of neuropsychiatric SLE. Nat Rev Rheumatol. 2014;10:338-47. doi:10.1038/nrrheum.2014.15; Govoni M, Bortoluzzi A, Padovan M, et al. The diagnosis and clinical management of the neuropsychiatric manifestations of lupus. J Autoimmun. 2016;74:41-72. doi:10.1016/j.jaut.2016.06.013; Stock AD, Wen J, Putterman C. Neuropsychiatric lupus, the blood brain barrier, and the TWEAK/Fn14 pathway. Front Immunol. 2013;4:484. doi:10.3389/fimmu.2013.00484; Fanouriakis A, Pamfil C, Rednic S, et al. Is it primary neuropsychiatric systemic lupus erythematosus? Performance of existing attribution models using physician judgment as the gold standard. Clin Exp Rheumatol. 2016;34(5):910-7. Epub 2016 Jul 26.; Ho RC, Thiaghu C, Ong H. A meta-analysis of serum and cerebrospinal fluid autoantibodies in neuropsychiatric systemic lupus erythematosus. Autoimmun Rev. 2016;15:124-38. doi:10.1016/j.autrev.2015.10.003; Kivity S, Agmon-Levin N, Zandman-Goddard G, et al. Neuropsychiatric lupus: a mosaic of clinical presentations. BMC Med. 2015;13:43. doi:10.1186/s12916-015-0269-8. PMid:25858312; Gladman DD, Urowitz B, Rahman P, et al. Accrual of organ damage over time in patients with systemic lupus erythematosus. J Rheumatol. 2003;30(9):1955-9.; Piga M, Peltz MT, Montaldo C, et al. Twenty-year brain magnetic resonance imaging follow-up study in systemic lupus erythematosus: factors associated with accrual of damage and central nervous system involvement. Autoimmun Rev. 2015;14(6):510-6. doi:10.1016/j.autrev.2015.01.010; Govoni M, Bombardieri S, Bortoluzzi A, et al. Factors and comorbidi-ties associated with first central nervous system neuropsychiatric event in systemic lupus erythematosus: does a risk profile exist? A large multicenter retrospective cross sectional study on 959 Italian patients. Rheumatology (Oxford). 2012;51:157-68. doi:10.1093/rheumatology/ker310
-
3Academic Journal
Συγγραφείς: G. M. Koilubaeva, E. A. Aseeva, S. K. Solovyev, N. Yu. Nikishina, E. L. Nasonov, N. P. Tkachenko, E. R. Karimova, A. Zh. Zhumakadyrova, A. A. Moldobaeva, E. Zh. Dzhishambaev, Г. М. Койлубаева, Е. А. Асеева, С. К. Соловьев, Н. Ю. Никишина, Е. Л. Насонов, Н. П. Ткаченко, Э. Р. Каримова, А. Ж. Жумакадырова, А. А. Молдобаева, Э. Ж. Джишамбаев
Πηγή: Rheumatology Science and Practice; Vol 57, No 5 (2019); 532-538 ; Научно-практическая ревматология; Vol 57, No 5 (2019); 532-538 ; 1995-4492 ; 1995-4484
Θεματικοί όροι: киргизская когорта, neuropsychiatric manifestations, central nervous system, peripheral nervous system, Kyrgyz cohort, нейропсихические проявления, центральная нервная система, периферическая нервная система
Περιγραφή αρχείου: application/pdf
Relation: https://rsp.mediar-press.net/rsp/article/view/2787/1891; Насонов ЕЛ. Клинические рекомендации по ревматологии. 2-е изд., испр. и доп. Москва: ГЭОТАР-Медиа; 2010. С. 429-81.; Vivaldo JF, de Amorim JC, Julio PR, et al. Definition of NPSLE: Does the ACR Nomenclature Still Hold? Front Med (Lausanne). 2018 May;31(5):138. doi:10.3389/fmed.2018.00138. eCollection 2018.; Иванова ММ, Близнюк ОИ, Тодау ФИ, Туманова АА. Поражение центральной нервной системы при системной красной волчанке. Клиническая медицина. 1989;(2):93-7.; Hanly JG, Urowitz MB, Sanchez-Guerrero J, et al. Neuropsychiatric events at the time of diagnosis of systemic lupus erythematosus: an international inception cohort study. Arthritis Rheum. 2007;56(1):265-73. doi:10.1002/art.22305; Kivity S, Agmon-Levin N, Zandman-Goddard G, et al. Neuropsychiatric lupus: a mosaic of clinical presentations. BMC Medicine. 2015;13:48. doi:10.1186/s12916-015-0269-9; The American of Rheumatology nomenclature and case definitions for neuropsychiatric lupus syndromes. Arthritis Rheum. 1999;42:599-608. doi:10.1002/1529-0131(199904)42:43.0.CO;2-F; Иванова ММ, Близнюк ОИ, Щекутьев ГА, Пушкова ОВ. Диагностика поражения центральной нервной системы у больных системной красной волчанкой. Клиническая ревматология. 1991;(4):6-8.; Zirkzee EJ, Steup-Beekman GM, van der Mast RC, et al. Prospective study of clinical phenotypes in neuropsychiatric systemic lupus erythematosus; multidisciplinary approach to diagnosis and therapy. J Rheumatol. 2012;39(11):2118-26. doi:10.3899/jrheum.120545; Hochberg MC. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum. 1997;40(9):1725. doi:10.1002/art.1780400928; Petri M, Orbai A, Alarson G, et al. Derivation and validation of the Systemic Lupus International Collaborating Clinics Classification Criteria for Systemic lupus erythematosus. Arthritis Rheum. 2012;64(8):2677-86. doi:10.1002/art.34473; Gladman DD, Ibanez D, Urowitz MB. Systemic lupus erythematosus disease activity index 2000. J Rheumatol. 2002;29:288-91.; Тареева ИЕ, Янушкевич ТН. Волчаночный нефрит у мужчин и женщин. Ревматология. 1985;(2):14-6.; Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group. KDIGO 2012 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease. Kidney Int. 2013;3 Suppl:1-150.; Zhang X. A study of effects of estrogen receptor and contrasupressor T cell subtype in pathogenesis of SLE. Rev Esp Rheum. 1993;20:420.; Magro-Checa C, Zirkzee EJ, Huizinga TW, et al. Management of neuropsychiatric systemic lupus erythematosus: current approaches and future perspectives. Drugs. 2016;76:459-83. doi:10.1007/s40265-015-0534-3; Hanly JG, Urowitz MB, Sanchez-Guerrero J, et al. Systemic Lupus International Collaborating Clinics. Neuropsychiatric events at the time of diagnosis of systemic lupus erythematosus: An international inception cohort study. Arthritis Rheum. 2007;56(1):265-73. doi:10.1002/art.22305; Everett CM, Graves TD, Lad S, et al. Aggressive CNS lupus vasculitis in the absence of systemic disease activity. Rheumatology (Oxford). 2008;47:107-9. doi:10.1093/rheumatology/kem264; Johnson RT, Richardson EP. The neurological manifestations of systemic lupus erythematosus. Medicine (Baltimore). 1968;47:337-69. doi:10.1097/00005792-196807000-00002; Kleinig TJ, Koszyca B. Fulminant leucocytoclastic brainstem vasculitis in a patient with otherwise indolent systemic lupus erythematosus. Lupus. 2009;18:486-90. doi:10.1177/0961203308101548; Rizos T, Siegelin M, Hä hnel S, et al. Fulminant onset of cerebral immunocomplex vasculitis as first manifestation of neuropsychiatric systemic lupus erythematosus (NPSLE). Lupus. 2009;18:361-3. doi:10.1177/0961203308097448; Rowshani AT, Remans P, Rozemuller A, Tak PP. Cerebral vasculitis as a primary manifestation of systemic lupus erythematosus. Ann Rheum Dis. 2005;64:784-6. doi:10.1136/ard.2004.026542; Gerli R, Caponi L, Tincani A, et al. Clinical and serological associations of ribosomal P autoantibodies in systemic lupus erythematosus: Prospective evaluation in a large cohort of Italian patients. Rheumatology. 2002;41:1357-66. doi:10.1093/rheumatology/41.12.1357; Hermosillo-Romo D, Brey RL. Diagnosis and management of patients with neuropsychiatric systemic lupus erythematosus (NPSLE). Best Pract Res Clin Rheumatol. 2002;16(2):229-44. doi:10.1053/berh.2001.0223; Purandare KN, Wagle AC, Parker SR. Psychiatric morbidity in patients with systemic lupus erythematosus. Q J Med. 1999;92:283-6. doi:10.1093/qjmed/92.5.283; Kakati S, Barman B, Ahmed SU, Hussain M. Neurological manifestations in systemic lupus erythematosus: A Single Centre Study from North East India. J Clin Diagn Res Int Med Sect 2017;11(01):OC05-OC09. doi:10.7860/JCDR/2017/23773.9280; Khajezadeh MA, Zamani G, Moazzami B, et al. Neuropsychiatric involvement in juvenile-onset systemic lupus erythematosus. Neurol Res Int. 2018 May 29;2548142. doi:10.1155/2018/2548142; Szmyrka M, Pokryszko-Dragan A, Slotwinski K, et al. Cognitive impairment, event-related potentials and immunological status in patients with systemic lupus erythematosus. Adv Clin Exp Med. 2018 Jul 2. doi:10.17219/acem/76711; Brey RL, Holliday SL, Saklad AR, et al. Neuropsychiatric syndromes in lupus. Neurology. 2002;58:1214-20. doi:10.1212/WNL.58.8.1214; Mikdashi J, Handwerger B. Predictors of neuropsychiatric damage systemic lupus erythematosus: data from the Maryland lupus cohort. J Rheumatol. 2004;43:1555-60. doi:10.1093/rheumatology/keh384; Mok CC, Mak A, Chu WP, et al. Long-term survival of southern Chinese patients with systemic lupus erythematosus: a prospective study of all age-groups. Medicine (Baltimore). 2005;84:218-24. doi:10.1097/01.md.0000170022.44998.d1; Whitelaw DA, Spangenberg JJ, Rickman R, et al. Association between the antiphospholipid antibody syndrome and neuropsychological impairment in SLE. Lupus. 1999;8:444-8. doi:10.1177/096120339900800606; Lukjanowcz M, Brzosko M. Myelitis in the course of systemic lupus erythematosus. Polskie Arch Med Wew. 2009;119(1-2):67-72. doi:10.20452/pamw.608; Krishnan C, Kaplin AI, Deshpande DM, et al. Transverse myelitis: pathogenesis, diagnosis and treatment. Front Biosci. 2004;9:1483-99. doi:10.2741/1351; Toledano P, Orueta R, Rodriguez-Pinto I, et al. Peripheral nervous system involvement in systemic lupus erythematosus: Prevalence, clinical and immunological characteristics, treatment and out-come of a large cohort from a single centre. Autoimmun Rev. 2017 Jul;16(7):750-5. doi:10.1016/j.autrev.2017.05.011; Saigal R, Bhargav R, Goyal L, et al. Peripheral neuropathy in systemic lupus erythematosus: Clinical and electrophysiological properties and their association with disease activity parameters. J Assoc Phys India. 2015 Dec;63(12):15-9.; Huynh C, Ho SL, Fong KY, et al. Peripheral neuropathy in systemic lupus erythematosus. J Clin Neurophysiol. 1999;16(2):164-8. doi:10.1097/00004691-199903000-00010; Лайсэк РП, Левинсон АИ. Невропатии при заболеваниях соединительной ткани. Заболевания периферической нервной системы: Пер. с англ. Москва: Медицина; 1987. 280 с.; Mondelli M, Romano C, Porta P, Rossi A. Electrophysiological evidence of «nerve entrapment syndromes» and subclinical peripheral neuropathy in progressive systemic sclerosis. J Neurol. 1995;242:185-94. doi:10.1007/BF00919590
-
4Academic Journal
Συγγραφείς: G. M. Koylubaeva, T. M. Reshetnyak, E. A. Aseeva, K. S. Solovyov, A. S. Dzhumagulova, N. P. Tkachenko, E. R. Karimovа, A. Zh. Zhumakadyrova, E. Zh. Dzhishambaev, K. A. Dzhailobayeva, E. L. Nasonov, Г. М. Койлубаева, Т. М. Решетняк, Е. А. Асеева, С. К. Соловьев, А. С. Джумагулова, Н. П. Ткаченко, Э. Р. Каримова, А. Ж. Жумакадырова, Э. Ж. Джишамбаев, К. А. Джайлобаева, Е. Л. Насонов
Πηγή: Rheumatology Science and Practice; Vol 57, No 1 (2019); 17-27 ; Научно-практическая ревматология; Vol 57, No 1 (2019); 17-27 ; 1995-4492 ; 1995-4484
Θεματικοί όροι: киргизская когорта, neuropsychic manifestations, central nervous system, peripheral nervous system, Kyrgyz cohort, нейропсихические проявления, центральная нервная система, периферическая нервная система
Περιγραφή αρχείου: application/pdf
Relation: https://rsp.mediar-press.net/rsp/article/view/2669/1796; Насонов ЕЛ. Клинические рекомендации по ревматологии. 2-е изд., испр. и доп. Москва: ГЭОТАР-Медиа; 2010. C. 429-81 [Nasonov EL. Klinicheskie rekomendatsii po revmatologii [Clinical guidelines for rheumatology]. 2nd ed. Moscow: GEOTAR-Media; 2010. P. 429-81 (In Russ.)].; Jeltsch-David H, Muller S. Neuropsychiatric systemic lupus erythematosus: pathogenesis and biomarkers. Nat Rev Neurol. 2014;10(10):579-96. doi:10.1038/nrneurol.2014.148 PMid:25201240; Zhang X. A study of effects of estrogen receptor and contrasupressor T cell subtype in pathogenesis of SLE. Rev Esp Rheum. 1993;20:420.; Magro-Checa C, Zirkzee EJ, Huizinga TW, et al. Management of Neuropsychiatric Systemic Lupus Erythematosus: Current Approaches and Future Perspectives. Drugs. 2016;76:459-83. doi:10.1007/s40265-015-0534-3 PMid: 26809245; Petri M, Orbai A, Alarson G, et al. Derivation and validation of the Systemic Lupus International Collaborating Clinics Classification Criteria for Systemic lupus erythematosus. Arthritis Rheum. 2012;64(8):2677-86. doi:10.1002/art.34473; The American of Rheumatology nomenclature and case definitions for neuropsychiatric lupus syndromes. Arthritis Rheum. 1999;4:599-608. doi:10.1002/1529-0131(199904)42:43.0.CO;2-F; Мотовилов АА, Травина ИВ, Проказова НВ. Антитела к нейтральным гликосфинголипидам и ганглиозидам у больных системной красной волчанкой с поражением центральной нервной системы. Клиническая ревматология. 1995;(1):36-8 [Motovilov AA, Travina IV, Prokazova NV. Antibodies to neutral glycosphingolipids and gangliosides in patients with systemic lupus erythematosus with central nervous system damage. Klinicheskaya Revmatologiya. 1995;(1):36-8 (In Russ.)].; Насонова ВА, Сперанский АИ. Клинико-иммунологические субтипы системной красной волчанки. В кн.: Современные проблемы ревматологии. 1-й Съезд ревматологов России. Тезисы докладов. Оренбург; 1993. С. 121-2 [Nasonova VA, Speranskii AI. Clinical and immunological subtypes of systemic lupus erythematosus. In: Sovremennye problemy revmatologii. 1-i S"ezd revmatologov Rossii. Tezisy dokladov [Current problems of rheumatology. 1st Congress of Rheumatologists of Russia. Abstracts]. Orenburg; 1993. P. 121-2 (In Russ.)].; Пизова НВ, Шилкина НП, Спирин НН. Иммунные повреждения нервной системы при некоторых формах ревматических заболеваний. Журнал неврологии и психиатрии. 2005;(2):73-8 [Pizova NV, Shilkina NP, Spirin NN. Immune damage to the nervous system in some forms of rheumatic diseases. Zhurnal Nevrologii i Psikhiatrii. 2005;(2):73-8 (In Russ.)].; Hanly JG. Diagnosis and management of neuropsychiatric SLE. Nat Rev Rheumatol. 2014;10:338-47. doi:10.1038/nrrheum.2014.15. PMid:24514913; Govoni M, Bortoluzzi A, Padovan M, et al. The diagnosis and clinical management of the neuropsychiatric manifestations of lupus. J Autoimmun. 2016;74:41-72. doi:10.1016/j.jaut.2016.06.013. PMID:27427403; Stock AD, Wen J, Putterman C. Neuropsychiatric lupus, the blood brain barrier, and the TWEAK/Fn14 pathway. Front Immunol. 2013;4:484. doi:10.3389/fimmu.2013.00484; Fanouriakis A, Pamfil C, Rednic S, et al. Is it primary neuropsychiatric systemic lupus erythematosus? Performance of existing attribution models using physician judgment as the gold standard. Clin Exp Rheumatol. 2016;34(5):910-7. Epub 2016 Jul 26. PMID: 27463840.; Ho RC, Thiaghu C, Ong H, et al. A meta-analysis of serum and cerebrospinal fluid autoantibodies in neuropsychiatric systemic lupus erythematosus. Autoimmun Rev. 2016;15:124-38. doi:10.1016/j.autrev.2015.10.003; Kivity S, Agmon-Levin N, Zandman-Goddard G, et al. Neuropsychiatric lupus: a mosaic of clinical presentations. BMC Med. 2015;13:43. doi:10.1186/s12916-015-0269-8. PMID:25858312; Алекберова ЗС, Решетняк ТМ, Рaденска-Лоповок СГ. Васкулопатия у больных системной красной волчанкой с антифосфолипидным синдромом. Терапевтический архив. 1995;(5):41-4 [Alekberova ZS, Reshetnyak TM, RadenskaLopovok SG. Vasculopathy in patients with systemic lupus erythematosus with antiphospholipid syndrome. Terapevticheskii Arkhiv. 1995;(5):41-4 (In Russ.)].; Hirohata S, Sakuma Y, Matsueda Y, et al. Role of serum autoantibodies in blood brain barrier damages in neuropsychiatric systemic lupus erythematosus. Clin Exp Rheumatol. 2018;24. PMID: 29846157.; Cohen D, Rijnink EC, Nabuurs RJ, et al. Brain histopathology in patients with systemic lupus erythematosus: identification of lesions associated with clinical neuropsychiatric lupus syndromes and the role of complement. Rheumatology (Oxford). 2017;56(1):77-86. doi:10.1093/rheumatology/kew341. Epub 2016 Oct 25.; Иванова ММ, Близнюк ОИ, Щекутьев ГА, Пушкова ОВ. Диагностика поражения центральной нервной системы у больных системной красной волчанкой. Клиническая ревматология. 1991;(4):6-8 [Ivanova MM, Bliznyuk OI, Shchekut'ev GA, Pushkova OV. Diagnosis of central nervous system lesions in patients with systemic lupus erythematosus. Klinicheskaya Revmatologiya. 1991;(4):6-8 (In Russ.)].; Zirkzee EJ, Steup-Beekman GM, van der Mast RC, et al. Prospective study of clinical phenotypes in neuropsychiatric systemic lupus erythematosus; multidisciplinary approach to diagnosis and therapy. J Rheumatol. 2012;39(11):2118-26. doi:10.3899/jrheum.120545; Vivaldo JF, de Amorim JC, Julio PR, et al. Definition of NPSLE: Does the ACR Nomenclature Still Hold? Front Med (Lausanne). 2018 May 31;5:138. doi:10.3389/fmed.2018.00138; Иванова ММ, Близнюк ОИ, Тодау ФИ, Туманова АА. Поражение центральной нервной системы при системной красной волчанке. Клиническая медицина. 1989;(2):93-7 [Ivanova MM, Bliznyuk OI, Todau FI, Tumanova AA. Central nervous system damage in systemic lupus erythematosus. Klinicheskaya Meditsina. 1989;(2):93-7 (In Russ.)].; Hanly JG, Urowitz MB, Sanchez-Guerrero J, et al. Neuropsychiatric events at the time of diagnosis of systemic lupus erythematosus: an international inception cohort study. Arthritis Rheum. 2007;56(1):265-73. doi:10.1002/art.22305; Иванова ММ. ЦНС-люпус: проблемы и достижения (результаты 10-летнего – клинико-инструментального исследования). Терапевтический архив. 2001;(6):25-9 [Ivanova MM. CNS-lupus: problems and achievements (results of a 10-year clinical and instrumental study). Terapevticheskii Arkhiv. 2001;(6):25-9 (In Russ.)].; Харченко СА, Грехов РА, Сулейманова ГП и др. Психологические особенности больных системной красной волчанкой. Современные проблемы науки и образования. 2015;(5) [Kharchenko SA, Grekhov RA, Suleimanova GP, et al. Psychological features of patients with systemic lupus erythematosus. Sovremennye Problemy Nauki i Obrazovaniya. 2015;(5) (In Russ.)].; Hussein MA, Elsabagh YA, Hosny A, Elgendy H. Silent cerebral MRI findings in lupus nephritis patients: is it clinically significamt? J Adv Res. 2017 Nov;20(9):63-7. doi:10.1016/j.jare.2017.10.011; Койлубаева ГМ, Асеева ЕА, Соловьев СК и др. Клинические проявления, варианты течения и исходы системной красной волчанки у жителей Кыргызстана. Научно-практическая ревматология. 2016;54(4):432-41 [Koilubaeva GM, Aseeva EA, Solovyev SK, et al. Clinical mani festations, courses, and outcomes of systemic lupus erythematosus in the dwellers of Kyrgyzstan. Nauchno-Prakticheskaya Revmatologiya = Rheumatology Science and Practice. 2016;54(4):432-41 (In Russ.)]. doi:10.14412/1995-4484-2016-432-441].; Hochberg MC. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum. 1997;40(9):1725. doi:10.1002/art.1780400928; Gladman DD, Ibanez D, Urowitz MB. Systemic lupus erythematosus disease activity index 2000. J Rheumatol. 2002;29:288-91.; Unterman A, Nolte JE, Boaz M, et al. Neuropsychiatric syndromes in systemic lupus erythematosus: a meta-analysis. Semin Arthritis Rheum. 2011;41(1):1-11. doi:10.1016/j.semarthrit.2010.08.001; Benseler S, Silverman E. Neuropsychiatric involvement in pediatric systemic lupus erythematosus. Lupus. 2007;16:564-71. doi:10.1177/0961203307078971; Popescu A, Kao AH. Neuropsychiatric Systemic Lupus Erythematosus. Curr Neuropharmacol. 2011;9(3):449-57. doi:10.2174/157015911796557984; Brey RL. Neuropsychiatric lupus: clinical and imaging aspects. Bull NYU Hosp Jt Dis. 2007;65(3):194-9.; Zirkzee EJ, Huizinga TW, Bollen EL, et al. Mortality in neuropsychiatric systemic lupus erythematosus (NPSLE). Lupus. 2014;23(1):31-8. doi:10.1177/0961203313512540; Dö ndü Üskü daz Cansu, Hava Üskü dar Teke, Gengiz Korkmaz. Survival analysis of Turkish patients with systemic lupus erythematosus: older age of diagnosis affects mortality. Arch Rheumatol. 2017;32(2):141-8. doi:10.5606/ArchRheumatol.2017.6173; Morad CS, Mansour HE, Ibrahim SE, et al. Subclinical neuropsychiatric dysfunctions in female patients with systemic lupus erythematosus. Egyptian Rheumatol Rehabil. 2018;45:49-56. doi:10.4103/err.err_46_17; Ainiala H, Hietaharju A, Loukkola J, et al. Validity of the new American College of Rheumatology criteria for neuropsychiatric lupus syndromes: a population-based evaluation. Arthritis Rheum. 2001;45(5):419-23. doi:10.1002/1529-0131(200110)45:53.0.CO;2-X; Hanly JG. ACR classification criteria for systemic lupus erythematosus: limitations and revisions to neuropsychiatric variables. Lupus. 2004;13(11):861-4. doi:10.1191/0961203304lu2024oa; Birnbaum J, Petri M, Thompson R, et al. Distinct subtypes of myelitis in systemic lupus erythematosus. Arthritis Rheum. 2009;60(11):3378-87. doi:10.1002/art.24937; Barber CE, Leclerc R, Gladman DD, et al. Posterior reversible encephalopathy syndrome: an emerging disease manifestation in systemic lupus erythematosus. Semin Arthritis Rheum. 2011;41(3):353-63. doi:10.1016/j.semarthrit.2011.07.001; Ahn GY, Kim D, Won S, et al. Prevalence, risk factors, and impact on mortality of neuropsychiatric lupus: a prospective, single-center study. Lupus. 2018 Jul;27(8):1338-47. doi:10.1177/0961203318772021; Pego-Reigosa JM, Isenberg DA. Psychosis due to systemic lupus erythematosus: characteristics and long-term outcome of this rare manifestation of the disease. Rheumatology. 2008;47:1498-502. doi:10.1093/rheumatology/ken260; Rowshani AT, Remans P, Rozemuller A, Tak PP. Cerebral vasculitis as a primary manifestation of systemic lupus erythematosus. Ann Rheum Dis. 2005;64:784-6. doi:10.1136/ard.2004.026542; Gerli R, Caponi L, Tincani A, et al. Clinical and serological associations of ribosomal P autoantibodies in systemic lupus erythematosus: Prospective evaluation in a large cohort of Italian patients. Rheumatology. 2002;41:1357-66. doi:10.1093/rheumatology/41.12.1357; Hermosillo-Romo D, Brey RL. Diagnosis and management of patients with neuropsychiatric systemic lupus erythematosus (NPSLE). Best Pract Res Clin Rheumatol. 2002;16(2):229-44. doi:10.1053/berh.2001.0223; Purandare KN, Wagle AC, Parker SR. Psychiatric morbidity in patients with systemic lupus erythematosus. Q J Med. 1999;92:283-6. doi:10.1093/qjmed/92.5.283; Kakati S, Barman B, Ahmed SU, Hussain M. Neurological Manifestations in Systemic Lupus Erythematosus: A Single Centre Study from North East India. J Clin Diagn Res Intern Med Sect. 2017;11(01):0C05-OCO9. doi:10.7860/JCDR/2017/23773.9280; Khajezadeh MA, Zamani G, Moazzami B, et al. Neuropsychiatric Involvement in Juvenile-Onset Systemic Lupus Erythematosus. Neurol Res Int. 2018 May 29:2548142. doi:10.1155/2018/2548142; Szmyrka M, Pokryszko-Dragan A, Slotwinski K, et al. Cognitive impairment, event-related potentials and immunological status in patients with systemic lupus erythematosus. Adv Clin Exp Med. 2018 Jul 2. doi:10.17219/acem/76711; Brey RL, Holliday SL, Saklad AR, et al. Neuropsychiatric syndromes in lupus. Neurology. 2002;58:1214-20. doi:10.1212/WNL.58.8.1214PMid:11971089; Mikdashi J, Handwerger B. Predictors of neuropsychiatric damage systemic lupus erythematosus: data from the Maryland lupus cohort. J Rheumatol. 2004;43:1555-60. doi:10.1093/rheumatology/keh384; Mok CC, Mak A, Chu WP, et al. Long-term survival of southern Chinese patients with systemic lupus erythematosus: a prospective study of all age-groups. Medicine (Baltimore). 2005;84:218-24. doi:10.1097/01.md.0000170022.44998.d1; Whitelaw DA, Spangenberg JJ, Rickman R, et al. Association between the antiphospholipid antibody syndrome and neuropsychological impairment in SLE. Lupus. 1999;8:444-8. doi:10.1177/096120339900800606; Everett CM, Graves TD, Lad S, et al. Aggressive CNS lupus vasculitis in the absence of systemic disease activity. Rheumatology (Oxford). 2008;47:107-9. doi:10.1093/rheumatology/kem264; Johnson RT, Richardson EP. The neurological manifestations of systemic lupus erythematosus. Medicine (Baltimore). 1968;47:337-69. doi:10.1097/00005792-196807000-00002; Kleinig TJ, Koszyca B. Fulminant leucocytoclastic brainstem vasculitis in a patient with otherwise indolent systemic lupus erythematosus. Lupus. 2009;18:486-90. doi:10.1177/0961203308101548; Rizos T, Siegelin M, Hä hnel S, et al. Fulminant onset of cerebral immunocomplex vasculitis as first manifestation of neuropsychiatric systemic lupus erythematosus (NPSLE). Lupus. 2009;18:361-3. doi:10.1177/0961203308097448; Lukjanowcz M, Brzosko M. Myelitis in the course of systemic lupus erythematosus. Polskie Arch Med Wew. 2009;119(1-2):67-72.; Krishnan C, Kaplin AI, Deshpande DM, et al. Transverse myelitis: pathogenesis, diagnosis and treatment. Front Biosci. 2004;9:1483-99. doi:10.2741/1351; Toledano P, Orueta R, Rodriguez-Pinto I, et al. Peripheral nervous system involvement in systemic lupus erythematosus: Prevalence, clinical and immunological characteristics, treatment and outcome of a large cohort from a single centre. Autoimmun Rev. 2017 Jul;16(7):750-5. doi:10.1016/j.autrev.2017.05.011; Saigal R, Bhargav R, Goyal L, et al. Peripheral Neuropathy in Systemic Lupus Erythematosus: Clinical and Electrophysiological Properties and their Association with Disease Activity Parameters. J Assoc Physicians India. 2015 Dec;63(12):15-9.; Huynh C, Ho SL, Fong KY, et al. Peripheral neuropathy in systemic lupus erythematosus. J Clin Neurophysiol. 1999;16(2):164-8. doi:10.1097/00004691-199903000-00010; Лайсэк РП, Левинсон АИ. Невропатии при заболеваниях соединительной ткани. Заболевания периферической нервной системы. Москва: Медицина; 1987. 280 с. [Laisek RP, Levinson AI. Nevropatii pri zabolevaniyakh soedinitel'noi tkani. Zabolevaniya perifericheskoi nervnoi sistemy [Neuropathy in connective tissue diseases. Peripheral nervous system diseases]. Moscow: Meditsina; 1987. 280 p. (In Russ.)].; Mondelli M, Romano C, Porta P, Rossi A. Electrophysiological evidence of «nerve entrapment syndromes» and subclinical peripheral neuropathy in progressive systemic sclerosis. J Neurol.